Corixa and Lorantis Announce Joint Collaboration to Develop Vaccine

Corixa, a developer of immunotherapeutics, and Lorantis, a Cambridge, UK-based immunotherapy company, have announced a joint collaboration in which the companies will continue the development of a therapeutic hepatitis B vaccine, containing Corixa's RC-529 adjuvant and Lorantis' CV-1831, a hepatitis B core antigen that was previously owned by Apovia. This collaboration builds on the initial research and development conducted by Corixa and Apovia for the development of a therapeutic vaccine for the treatment of hepatitis B.

Yahoo News (http://biz.yahoo.com/bw/050303/35028_1.html)